ATE474593T1 - Behandlung von allergischen erkrankungen unter verwendung eines modulators des notch signaling pathway - Google Patents

Behandlung von allergischen erkrankungen unter verwendung eines modulators des notch signaling pathway

Info

Publication number
ATE474593T1
ATE474593T1 AT04722319T AT04722319T ATE474593T1 AT E474593 T1 ATE474593 T1 AT E474593T1 AT 04722319 T AT04722319 T AT 04722319T AT 04722319 T AT04722319 T AT 04722319T AT E474593 T1 ATE474593 T1 AT E474593T1
Authority
AT
Austria
Prior art keywords
modulator
treatment
signaling pathway
allergic diseases
notch signaling
Prior art date
Application number
AT04722319T
Other languages
English (en)
Inventor
Mark William Bodmer
Emmanuel Cyrille Pascal Briend
Brian Robert Champion
Andrew Christopher Lennard
Grahame James Mckenzie
Silvia Ragno
Tamara Tugal
George Albert Ward
Lesley Lynn Young
Original Assignee
Celldex Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0306583A external-priority patent/GB0306583D0/en
Priority claimed from GB0306582A external-priority patent/GB0306582D0/en
Priority claimed from GB0306640A external-priority patent/GB0306640D0/en
Priority claimed from GB0306621A external-priority patent/GB0306621D0/en
Priority claimed from GB0306622A external-priority patent/GB0306622D0/en
Priority claimed from GB0306626A external-priority patent/GB0306626D0/en
Priority claimed from GB0306644A external-priority patent/GB0306644D0/en
Priority claimed from GB0306624A external-priority patent/GB0306624D0/en
Priority claimed from GB0306651A external-priority patent/GB0306651D0/en
Priority claimed from GB0306654A external-priority patent/GB0306654D0/en
Priority claimed from GB0306650A external-priority patent/GB0306650D0/en
Priority claimed from PCT/GB2003/001525 external-priority patent/WO2003087159A2/en
Priority claimed from GB0312062A external-priority patent/GB0312062D0/en
Priority claimed from PCT/GB2003/003285 external-priority patent/WO2004013179A1/en
Priority claimed from GB0323130A external-priority patent/GB0323130D0/en
Priority claimed from PCT/GB2004/000046 external-priority patent/WO2004060262A2/en
Priority claimed from PCT/GB2004/000263 external-priority patent/WO2004064863A1/en
Application filed by Celldex Therapeutics Ltd filed Critical Celldex Therapeutics Ltd
Publication of ATE474593T1 publication Critical patent/ATE474593T1/de
Application granted granted Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/35—Allergens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0635—B lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5154—Antigen presenting cells [APCs], e.g. dendritic cells or macrophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A61K2039/55527—Interleukins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/15—Transforming growth factor beta (TGF-β)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/26—Flt-3 ligand (CD135L, flk-2 ligand)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/40—Regulators of development
    • C12N2501/42—Notch; Delta; Jagged; Serrate

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Transplantation (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pulmonology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
AT04722319T 2003-03-21 2004-03-22 Behandlung von allergischen erkrankungen unter verwendung eines modulators des notch signaling pathway ATE474593T1 (de)

Applications Claiming Priority (18)

Application Number Priority Date Filing Date Title
GB0306583A GB0306583D0 (en) 2003-03-21 2003-03-21 Medical treatment
GB0306582A GB0306582D0 (en) 2003-03-21 2003-03-21 Medical treatment
GB0306626A GB0306626D0 (en) 2003-03-22 2003-03-22 Medical treatment
GB0306644A GB0306644D0 (en) 2003-03-22 2003-03-22 Medical treatment
GB0306624A GB0306624D0 (en) 2003-03-22 2003-03-22 Medical treatment
GB0306651A GB0306651D0 (en) 2003-03-22 2003-03-22 Medical treatment
GB0306654A GB0306654D0 (en) 2003-03-22 2003-03-22 Medical treatment
GB0306640A GB0306640D0 (en) 2003-03-22 2003-03-22 Medical treatment
GB0306621A GB0306621D0 (en) 2003-03-22 2003-03-22 Medical treatment
GB0306650A GB0306650D0 (en) 2003-03-22 2003-03-22 Medical treatment
GB0306622A GB0306622D0 (en) 2003-03-22 2003-03-22 Medical treatment
PCT/GB2003/001525 WO2003087159A2 (en) 2002-04-05 2003-04-04 Modulators of the notch signalling pathway and uses thereof in medical treatment
GB0312062A GB0312062D0 (en) 2003-05-24 2003-05-24 Medical treatment
PCT/GB2003/003285 WO2004013179A1 (en) 2002-08-03 2003-08-01 Conjugate of notch signalling pathway modulators and their use in medical treatment
GB0323130A GB0323130D0 (en) 2003-10-03 2003-10-03 Medical treatment
PCT/GB2004/000046 WO2004060262A2 (en) 2003-01-07 2004-01-07 Modulators of notch signalling for use in immunotherpapy
PCT/GB2004/000263 WO2004064863A1 (en) 2003-01-23 2004-01-23 Treatment of autoimmune diseases using an activator for the notch signaling pathway
PCT/GB2004/001252 WO2004082710A1 (en) 2003-03-21 2004-03-22 Treatment of allergic diseases using a modulator of the notch signaling pathway

Publications (1)

Publication Number Publication Date
ATE474593T1 true ATE474593T1 (de) 2010-08-15

Family

ID=36091380

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04722319T ATE474593T1 (de) 2003-03-21 2004-03-22 Behandlung von allergischen erkrankungen unter verwendung eines modulators des notch signaling pathway

Country Status (4)

Country Link
US (2) US20060205823A1 (de)
EP (1) EP1646400B1 (de)
AT (1) ATE474593T1 (de)
WO (1) WO2004082710A1 (de)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0123379D0 (en) * 2001-09-28 2001-11-21 Lorantis Ltd Modulators
US7906116B2 (en) * 2005-09-01 2011-03-15 Parkash Gill Methods for using and identifying modulators of Delta-like 4
US8128933B2 (en) 2005-11-23 2012-03-06 Acceleron Pharma, Inc. Method of promoting bone growth by an anti-activin B antibody
TW201940502A (zh) 2007-02-02 2019-10-16 美商艾瑟勒朗法瑪公司 衍生自ＡｃｔＲＩＩＢ的變體與其用途
KR101871510B1 (ko) 2008-06-26 2018-06-26 악셀레론 파마 인코포레이티드 액티빈-ａｃｔｒｉｉａ 길항물질을 투약하는 방법 및 치료된 환자의 모니터링
US8216997B2 (en) 2008-08-14 2012-07-10 Acceleron Pharma, Inc. Methods for increasing red blood cell levels and treating anemia using a combination of GDF traps and erythropoietin receptor activators
WO2012049312A1 (en) 2010-10-15 2012-04-19 Alk-Abelló A/S Suppression of a type 1 hypersensitivity immune response with an unrelated antigen
BR112013009068A2 (pt) 2010-10-15 2016-07-19 Alk Abelló As supressão de uma resposta imune de hipersensibilidade com antígeno não relacionado derivado de material fonte de alérgeno
WO2013147793A1 (en) * 2012-03-29 2013-10-03 Fleming Robert J Methods and compositions for modulating notch activity
AU2013248275B2 (en) * 2012-04-16 2017-03-30 Alk-Abello A/S Plant profilin polypeptides for use in non-specific allergy immunotherapy
EP2846818A1 (de) * 2012-05-10 2015-03-18 Institut National de la Santé et de la Recherche Médicale (INSERM) Immunmodulatorische verfahren unter verwendung von notch-agonisten
WO2014141064A1 (en) 2013-03-13 2014-09-18 Novartis Ag Notch2 binding molecules for treating respiratory diseases
US10010498B2 (en) 2014-06-04 2018-07-03 Acceleron Pharma Inc. Methods for treatment of amyotrophic lateral sclerosis with follistatin fusion proteins
CN106795224B (zh) 2014-06-04 2021-05-18 阿塞勒隆制药公司 用促滤泡素抑制素多肽治疗病症的方法和组合物
WO2016154601A1 (en) 2015-03-26 2016-09-29 Acceleron Pharma Inc. Follistatin-related fusion proteins and uses thereof
CN114689870B (zh) * 2016-06-02 2025-02-18 朋友股份有限公司 蛋变态反应的抗原

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB218068A (en) 1923-05-11 1924-07-03 Thomas Landye Mechanism for shifting belts from fast to loose pulleys and vice versa
WO1998020142A1 (en) * 1996-11-07 1998-05-14 Lorantis Limited Notch
US6887475B1 (en) * 1996-11-07 2005-05-03 Lorantis Limited Notch
GB9827604D0 (en) * 1998-12-15 1999-02-10 Lorantis Ltd Methods of immunosuppression
EP1410018A1 (de) 2001-07-25 2004-04-21 Lorantis Limited Methode zur detektion von modulatoren von notch signaltransduktion
AU2003255735A1 (en) 2002-08-03 2004-02-23 Lorantis Limited Conjugate of notch signalling pathway modulators and their use in medical treatment

Also Published As

Publication number Publication date
US20100303867A1 (en) 2010-12-02
WO2004082710A1 (en) 2004-09-30
US20060205823A1 (en) 2006-09-14
EP1646400A1 (de) 2006-04-19
EP1646400B1 (de) 2010-07-21

Similar Documents

Publication Publication Date Title
ATE474593T1 (de) Behandlung von allergischen erkrankungen unter verwendung eines modulators des notch signaling pathway
EA200600433A1 (ru) Сопряжённые гетероциклические соединения
ATE502633T1 (de) Cyclosporins zur behandlung und vorbeugung von augenerkrankungen
TNSN07027A1 (en) Pyrrolo-pyridine kinase modulators
MA31858B1 (fr) N-phenyl-bipyrrolidine-carboxamides substitues et utilisation therapeutique de ceux-ci
DE602004006536D1 (de) Bekämpfng von parasiten in tieren durch anwendung von imidazoä1,2-büpyridazinderivaten
DE60125335D1 (de) Azacyclische verbindungen zur verwendung in der behandlung von mit serotonin verwandten krankheiten
DE502005010615D1 (de) Mittel zur behandlung von entzündlichen erkrankungen
AR036401A1 (es) Incremento de la cantidad de celulas madre neuronales inducido por prolactina.
ATE476428T1 (de) Selektive modulatoren des östrogenrezeptors zur behandlung von vasomotorischen symptomen
ATE405261T1 (de) Verwendung von castanospermine derivaten in der behandlung von hepatitis c
CO6190616A2 (es) Carboxamidas n-fenil-bipirrolidina sustituidas y su uso terapeutico
DE60042035D1 (de) Verfahren und zusammensetzungen zur herstellung von ophtalmischen linsen
DE60204466D1 (de) Integrinhemmer zur behandlung von augenkrankheiten
ATE410424T1 (de) Spirocyclische cyclohexan-derivate
ATE396697T1 (de) Zuckerlacton enthaltende zusammensetzung zur haarbehandlung
ATE353645T1 (de) Verwendung von 2-oxo-1-pyrrolidin-derivaten zur herstellung eines arzneimittels zur behandlung von dyskinesia
NO20025405D0 (no) Modulatorer for TNF-alfa-signalisering
ATE542536T1 (de) 3-ä4-(dibenzoäb,füä1,4üoxazepin-11-yl)-piperazi - 1-ylü-2,2-dimethyl propansäure zur verwendung in der behandlung von schlafstörungen
ATE457027T1 (de) Substituierte 1,4,8-triazaspiroä4.5 decan-2-on- verbindungen zur behandlung von fettsucht
ATE324880T1 (de) Behandlung von mastalgie mit4-hydroxy-tamoxifen
RU2004115107A (ru) Способы профилактики и лечения инфекции, вызываемой флавивирусами у животных
DE602004010691D1 (de) Verwendung von xenon mit hypothermie zur behandlung von neugeborenen-asphyxie
EA201070494A1 (ru) МОДУЛЯТОРЫ γ-СЕКРЕТАЗЫ С АМИДНЫМИ СВЯЗЯМИ
ATE427141T1 (de) Vorrichtung zum bedecken von den augen

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties